Imaging patients with chronic kidney disease: CIN or NSF?;Imaging nel paziente con insufficienza renale cronica: CIN o NSF?

Radiologia Medica

Volumn 112, Issue 5, 2007, Pages 621-625

  Thomsen, H S ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Contrast media; Contrast induced nephropathy; Gadolinium; Nephrogenic systemic fibrosis; Renal disease

Indexed keywords

CONTRAST MEDIUM; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOLINIUM; GADOTERATE MEGLUMINE; IOBITRIDOL; IODINATED CONTRAST MEDIUM; IODIXANOL; IOHEXOL; IOMEPROL; IOPAMIDOL; IOPENTOL; IOPROMIDE; IOVERSOL; IOXAGLIC ACID; IOXILAN; METFORMIN;

CACHEXIA; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTRAST INDUCED NEPHROPATHY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIAGNOSTIC IMAGING; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG FATALITY; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; NEPHROGENIC SYSTEMIC FIBROSIS; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; RADIOLOGIST; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SKIN MANIFESTATION;

CONTRAST MEDIA; FIBROSIS; GADOLINIUM DTPA; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; MAGNETIC RESONANCE IMAGING; RISK FACTORS; SKIN DISEASES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34547813623     PISSN: 00338362     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11547-007-0168-y     Document Type: Review

References (12)

1. Thomsen HS (2006) Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Eur Radiol 16:2619-2621
2. Marckmann P, Skov L, Rossen K et al (2006) Nephrogenic systemic fibrosis: suspected etiological role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17:2359-2362
3. Thomsen HS, Morcos SK, Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR) (2005) In which patients should serum-creatinine be measured before contrast medium administration? Eur Radiol 15:749-754
4. Thomsen HS, Morcos SK (2006). Contrast-medium-induced nephropathy: is there a new consensus? A review of published guidelines. Eur Radiol 16:1835-1840
5. Barrett BJ, Carlisle EJ (1993) Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 188:171-178
6. Barrett BJ, Parfery PS (2006) Preventing nephropathy induced by contrast medium. N Engl J Med 354:379-386
7. Solomon R, DuMouchel W (2006) Contrast media and nephropathy. Findings from systematic analysis and Food and Drug Administration reports of adverse effects. Invest Radiol 41:651-660
8. Carraro M, Malalan F, Antonione R et al (1998) Effects of a dimeric vs. a monomeric nonionic contrast medium on renal function in patients with mild to moderate renal insufficiency: a double-blind, randomized clinical trial. Eur Radiol 8:144-147
9. Kolehmainen H, Soiva M (2003) Comparison of Xenetix 300 and Visipaque 320 in patients with renal failure. Eur Radiol 13:B32-B33
10. Barrett BJ, Katzberg RW, Thomsen HS et al (2006) Contrast induced nephropathy in patients with chronic kidney disease undergoing computed tomography. A double blind comparison of iodixanol and iopamidol. Invest Radiol 41:815-821
11. Morcos SK (2007) Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br J Radiol 80:73-76
12. EMEA Public Health Advisory 07.02.07 (2007) Available through www.esur.org. Accessed 14.03.07